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Mediators of Treatment Effect in the Back In Action Trial
Using Latent Growth Modeling to Take Change Over Time Into
Account
Gemma Mansell, PhD,* Jonathan C. Hill, PhD,*
Chris J. Main, PhD,* Michael Von Korﬀ, PhD,w
and Danie¨lle van der Windt, PhD*
Objectives: To test whether change in fear-avoidance beliefs was a
mediator of the eﬀect of treatment on disability outcome, and to
test an analytical approach, latent growth modeling, not often
applied to mediation analysis.
Methods: Secondary analysis was carried out on a randomized
controlled trial designed to compare an intervention addressing
fear-avoidance beliefs (n=119) with treatment as usual (n=121)
for patients with low back pain, which found the intervention to be
eﬀective. Latent growth modelling was used to perform a media-
tion analysis on the trial data to assess the role of change in fear-
avoidance beliefs on disability outcome. The product of coeﬃcients
with bias-corrected bootstrapped conﬁdence intervals was used to
calculate the mediating eﬀect.
Results: A statistically signiﬁcant mediating eﬀect of fear-avoidance
beliefs on the eﬀect of treatment on disability outcome was found
(standardized indirect eﬀect 0.35; bias-corrected 95% CI, 0.47
to 0.24). Poor ﬁt of the model to the data suggested that other
factors not accounted for in this model are likely to be part of the
same mediating pathway.
Discussion: Fear-avoidance beliefs were found to mediate the eﬀect of
treatment on disability outcome. Measurement of all potential mediator
variables in future studies would help to more strongly identify which
factors explain observed treatment eﬀects. Latent growth modelling was
found to be a useful technique to apply to studies of treatment media-
tion, suggesting that future studies could use this approach.
Key Words: mediation analysis, latent growth modeling, low back
pain
(Clin J Pain 2017;33:811–819)
Worldwide, the prevalence of low back pain (LBP) hasbeen estimated to be 9.4% (95% conﬁdence interval
[CI], 9.0-9.8),1 with lifetime prevalence estimates of between
51% and 84%.2 In the UK, LBP has been found to aﬀect
between 49% and 80% of the population at some point in
their lifetime, leading to high costs in terms of health care,
workplace absence,3 and impact on individual quality of
life.4 In the UK, musculoskeletal (MSK) conditions are
predominantly managed in primary care, with back pain
being the most common reason for patient health care
visits.5 Although the prognosis of patients with an acute
episode of LBP is often good,6,7 prognosis varies sub-
stantially for individual patients8 and persisting symptoms
are reported by many patients up to a year after their initial
consultation.6,8
Psychological factors (eg, fear-avoidance behaviors
and beliefs,9–17 catastrophizing thoughts,9,18 self-eﬃ-
cacy,9,19 and depression9,11,14,20) have been found to be
strong predictors of LBP outcomes and evidence suggests
that they are potentially important in inﬂuencing the eﬀect
of treatment. Guidelines on the management of LBP also
recommend screening for and management of psycho-
logical factors.21,22 However, it remains unclear how
interventions addressing psychological factors improve
patient outcomes,23 with mixed results being found in pri-
mary care populations in particular.24
To improve the eﬀectiveness of future interventions,
key factors explaining improved patient outcomes must be
identiﬁed to guide interventions.25,26 These factors, known
as treatment mediators, help explain how a treatment led to
an eﬀect on the outcome of interest27 by looking at which
factors change as a result of treatment, which are then
related to a change in the outcome.28,29
It has been acknowledged that just because a factor is
prognostic (has been found to be related to outcome) does
not mean it is necessarily causally related to outcome.24
Temporality (change over time) has been identiﬁed as
fundamental characteristic used to determine whether a
hypothesized treatment mediator is on a causal path-
way.29,30,31 For example, we may hypothesize that a treat-
ment designed to eﬀect fear avoidance caused a reduction
in fear-avoidance beliefs (FABs), which in turn led to
an improvement in patient function. However, the
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improvement in function could have occurred ﬁrst, which
led to the reduction in FABs. Without serial measurement
of both the proposed mediator and outcome, it is not
possible to know the order in which the change occurred.
To establish how changes in factors are related over time, at
least 3 measurements should be taken over diﬀerent time
points.29 Typically in intervention studies, measures are
only taken preintervention and postintervention, which
only gives information on whether a change takes place or
not, providing limited information about how a factor
changes over time as a result of the intervention.
The Back In Action study32 compared a psychological
intervention with treatment as usual in 240 patients with
LBP. The intervention centered on addressing patient’s
FABs and helping to improve their functioning. Measures
of psychological factors and function were taken at baseline
and at 4 follow-up points (2-, 6-, 12-, and 24-mo follow-up).
The intervention was successful in reducing disability across
all time points compared with the control group, with
statistically signiﬁcant diﬀerences observed between the 2
groups.32 The authors of the original study hypothesized
that the proposed intervention led to a reduction in FABs
and disability compared with usual care, but acknowledged
that the results were not able to identify which part(s) of the
intervention were most eﬀective.
A mediation analysis therefore provides an ideal
opportunity to test this potential treatment mechanism and
determine whether reductions in fear had a signiﬁcant
inﬂuence within the pathway leading to improved disability
outcomes in this trial. Latent growth modeling is a tech-
nique that allows the inclusion of multiple time points,
thereby providing a more accurate estimate of change.33
The aim of the analyses reported in this paper was to test
whether change in patients’ FABs mediated the relationship
between their allocation to the active intervention and the
change seen in disability in comparison with controls.
MATERIALS AND METHODS
Back In Action Intervention: Conceptual Model
The intervention used in the study was based on
approaches described by Balderson et al,34 which includes
assessing and addressing patients’ FABs, anxiety, and
activity limitations, performing a clinical assessment to rule
out red ﬂags indicating the need for prompt medical
intervention, and providing treatment recommendations in
line with goals set by the patient. The intervention included
4 visits with a physiotherapist or psychologist to identify
and address fears about pain, discuss activity and exercise
goals, and develop an action plan to try and resume normal
activities. Exercises provided were relevant to the patient’s
action plan and progress was reviewed at the end of treat-
ment. In addition to these visits, patients also received a
book on back pain self-management (Moore et al 1999,
cited in Von Korﬀ et al32) and a 40-minute video on back
pain (Patient Education Media Inc. 1996, cited in Von
Korﬀ et al32). The control group received treatment as
usual, which was heterogenous including medications,
physiotherapy, and a wide variety of other interventions.
Full details of the original trial are provided elsewhere.32
Outcome Measure
LBP-speciﬁc disability was measured by the 23-item
Roland-Morris Disability Questionnaire (RMDQ).35 A
higher score is suggestive of increased disability. This tool
has been found to have good test-retest reliability and
internal consistency in a primary care LBP population.36,37
In the present study, Cronbach a showed that the 23-item
RMDQ had good internal consistency (0.88).
Potential Mediator
FABs were measured using a modiﬁed version of the
Tampa Scale for Kinesiophobia (TSK) that contained 10 of
the original 17 items.38 The trial authors multiplied the
mean item score by 17 (the number of items in the original
tool) so that the scores from the shortened version could be
compared with the original version. A higher score suggests
increased FABs. This version of the TSK has not been
widely tested in terms of its psychometric properties, and in
the present study was found to have a Cronbach a value of
0.66, suggesting questionable internal consistency and also
potentially weakened associations between this measure
and measures of other variables in the analysis.
Statistical Analysis
Latent Growth Modelling
Latent growth modelling allows the examination of
variables across time, both within and between partic-
ipants.39–41 LGMs consist of an intercept latent factor and
a slope latent factor.42 The intercept factor represents the
starting point for the trajectory of a factor (its baseline
status), whereas the slope represents the change in the tra-
jectory of that factor over time. The use of the term
“trajectory” in this context refers to the path each indi-
vidual’s FABs and disability scores take over the measured
time points. To correctly specify a LGM, factor loadings
must be given to represent the intercept (usually all a value
of 1, as this is the point at which each individual starts) and
the slope factors (see below). LGMs can incorporate
models where change is not linear and where assessment
intervals are not equally spaced, provided that all partic-
ipants have been assessed at the same time points.39,43 It is
also possible to allow the model to estimate certain factor
loadings when the trajectory of a measure is not clear.39 It
should be noted that the factor loadings chosen are arbi-
trary and not reﬂective of actual score change on the
measures included in the model.
Although in the present analysis it is the slope that is
the factor of interest, the intercept is also important as
where a person starts in an intervention will have an impact
on their scores at subsequent points. Therefore, in this
LGM, covariance between the intercept and slope factors
was also included, as this gives an indication of whether
people who start at a lower or higher score for the mediator
or outcome change at lower or higher rates. To perform the
analysis, 3 steps were carried out, which are outlined below.
Step 1: Investigate the Shape of the Observed Growth
Trajectory (Change) for the Mediator and Outcome
Variables
Change over time in both the mediator and outcome
variables were estimated from the observed data, to ensure
that the factor scores for the slope factor represented the
observed trajectory and provided adequate ﬁt to the data.
This also allowed examination of diﬀerences in trajectories
between the treatment and control groups, which was
expected as the intervention had been shown to be eﬀective.
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Step 2: Combine the Trajectories of the Mediator and
Outcome Variables
The LGMs of the mediator and outcome were com-
bined into a single model so that the relationships with
intervention allocation could be investigated.39 This is
described as a parallel process model, where the observed
trajectories of the 2 measured variables are viewed as 2
separate processes that occur over the same period of
time.39 Including treatment group allocation as a covariate
(control=0, intervention=1) enabled examination of the
diﬀerences between scores in the intervention and control
groups.
Step 3: Full Mediation Model and Estimates of
Mediated Eﬀect (With Bootstrapped CIs)
The parallel process model was then used to estimate
the mediating eﬀect of FABs on the association between
treatment allocation and disability outcome using the
product of coeﬃcients approach, which is the analytical
approach recommended for carrying out mediation anal-
ysis.39,44,45 The statistical interpretation of mediation
analysis is made through separate eﬀects (Fig. 3). The c
path is the direct eﬀect of treatment on outcome, before
taking into account the eﬀects of any speciﬁc mediating
variables. Paths a and b make up the mediating pathway,
with the mediating eﬀect usually being described in the
literature as the product of coeﬃcients (ab or ab).46 The c´
path denotes the total eﬀect of the whole model (ab+ c).
Bias-corrected bootstrapped CIs were estimated to account
for the often non-normal distribution of the mediated eﬀect
and to provide an estimate of the precision of the mediated
eﬀect rather than just the statistical signiﬁcance.46 In the
present analysis, 1000 bias-corrected bootstrapped samples
were used to estimate 95% CIs.
Model Fit
Model ﬁt indices show how well the hypothesized
model ﬁts the observed data.47 In the present analysis, w2,
w2 divided by degrees of freedom (w2/df), Comparative Fit
Index (CFI), Root Mean Square Error of Approximation
(RMSEA), and Standardized Root Mean-square Residual
(SRMR) were examined. Good or adequate ﬁt is indicated
by a nonsigniﬁcant w2 value, a w2/df of between 2 and 5,
CFI of Z0.96, and a RMSEA and SRMR of r0.08.43,48
No one ﬁt index is seen as superior, and the exact cut-oﬀ
values are subject to debate.44 It has therefore been rec-
ommended that overall judgment is made on the basis of
several ﬁt indices.33 If the goodness-of-ﬁt indices did not
indicate good ﬁt, modiﬁcation indices were examined to
check whether the hypothesized model could be improved
by adding or removing factor loadings on speciﬁed paths.43
Changes to the original model were only made if the
modiﬁcation made theoretical sense and substantially
improved the model.43
Missing Data
Overall, follow-up rates in the original study were
good with <30 participants lost to follow-up by 24 months
in each group. Missing data were imputed using Expect-
ation Maximization, a single imputation method suitable
for use with small amounts of missing data.49 This method
assumes data are missing at random, which was checked
using Little’s MCAR (Missing Completely At Random)
test,50 which will be nonsigniﬁcant if the data are MCAR.
In addition to this test, baseline characteristics of
responders and nonresponders (split to show treatment and
control groups separately) were examined for baseline dif-
ferences between participants who responded or did not
respond at each time point (data not shown).
All analyses were carried out using Microsoft Excel,
SPSS PASW Version 18 and AMOS Version 19.
RESULTS
Study Sample Descriptive Data
The Back In Action trial recruited 240 adult partic-
ipants (119 in the treatment group and 121 in the control
group) aged between 25 and 64 years, with chronic LBP,
from primary care settings in Seattle, WA. Nonresponse
bias analysis indicated that there were diﬀerences in base-
line levels of pain intensity, FABs, disability, and pain
duration between responders and nonresponders in the 2
treatment groups. FABs and disability scores in the treat-
ment group were higher at baseline for those responding to
earlier follow-up points and lower at baseline for those
responding to later follow-up points. Pain duration in the
treatment group was shorter at baseline for responders to
follow-up compared with nonresponders.
The baseline characteristics of the study sample are
provided in Table 1, and indicate that a slightly higher
percentage of those in the treatment arm were female (65%
compared with 60%) and also had a slightly longer dura-
tion of pain (110 d compared with 97 d). However, these
diﬀerences were negligible and no other diﬀerences were
seen between treatment and control for the other variables
investigated. The mean (SD) scores for the potential
mediator (TSK) and outcome variable (RMDQ) in the 2
intervention groups are given in Table 2. The observed
trajectories of mean FABs and disability scores for the
treatment and control groups based on all measured time
points are presented in Figures 1 and 2. As expected, the
biggest mean change in the intervention group was between
baseline and the ﬁrst follow-up point of 2 months for both
the potential mediator (FABs) and the outcome variable
(disability).
TABLE 1. Baseline Characteristics of Study Population (n =240)
Mean (SD)
Variable
Treatment
(n=119)
Control
(n=121)
Age (y) 49.67 (9.02) 49.82 (9.77)
Sex (female) (%) 64.7 60.3
Education (median [range]) (y)* 6.00 (3-8) 6.00 (3-8)
Pain intensity (1-10)
Average last 3mo 5.71 (1.84) 5.83 (1.82)
Today 3.45 (2.49) 3.45 (2.57)
Pain duration (d) 110.50 (60.72) 97.39 (62.34)
Fear-avoidance beliefs (TSK: 10-
item version)
41.47 (8.79) 41.25 (8.22)
Disability (RMDQ: 23-item
version)
12.10 (5.49) 11.36 (5.67)
*Education was graded in 8 levels by asking participants what the
highest grade of year of school they completed. This ranged from 1 (<8y)
to 8 (postgraduate).
RMDQ indicates Roland-Morris Disability Questionnaire; TSK, Tampa
Scale for Kinesiophobia.
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The reduction in FABs and disability over the 2-
month intervention period was smaller for the control
group receiving usual care compared with the intervention
group. The intervention group showed a linear decrease in
disability scores compared with the control group, which
showed no change in disability over the ﬁrst 2 months and
also no change between 12- and 24-month follow-up. The
mean RMDQ scores at baseline showed a small diﬀerence
(0.7 point) despite randomization.
Step 1
The nonlinear trajectories needed to be accounted for
in the full LGM. The factor scores were therefore estimated
based on the observed trajectories, taking into account the
unequal measurement points. The factor scores were based
on the observed trajectory for both the treatment and
control groups combined, as the groups were compared
using the covariate of treatment group allocation in the full
mediation model. The factor scores for both the mediator
and outcome trajectories provided adequate ﬁt overall to
the data, as indicated by the goodness-of-ﬁt statistics (Fear-
avoidance: w142 =62.53, P<0.05, w2/df=4.47, CFI=
0.95, RMSEA=0.12 [95% CI, 0.09-0.15], SRMR=0.05;
Disability: w142 =49.95, P<0.05, w2/df=3.57, CFI=0.96,
RMSEA=0.10 [95% CI, 0.07-0.14], SRMR=0.04) and
were therefore used in the subsequent analyses (Fig. 3).
Although not every index suggested good ﬁt, the judgment
is based on the results of all the diﬀerent indices taken
together, so as the majority of indices suggested good or
adequate ﬁt, the trajectories were judged to be acceptable.
Step 2
The 2 separate models were then combined to test for
covariances between each of the intercept and slope factors
and explore how the potential mediator and outcome var-
iables related to each other, before adding the intervention
variable to complete the model. We assessed whether
change in the potential mediator was related to change in
the outcome variable. The model ﬁt statistics indicated that
the model provided fair ﬁt to the data overall. Modiﬁcation
indices showed that allowing covariation between the error
terms for the TSK and RMDQ 12-month follow-up scores
and between the error terms for the TSK and RMDQ 2-
month follow-up scores slightly improved model ﬁt
(w492 =154.88, P<0.05, w2/df=3.16, CFI=0.94, RMSEA=
0.10 [95% CI, 0.08-0.11], SRMR=0.05). As it is likely that
each of the measurement points are related to each other,
and that this may be reﬂected in related error variance,51 we
decided that allowing these covariances made theoretical
sense. Further modiﬁcations did not seem to be theoret-
ically plausible and therefore no further changes to the
model were made.
Table 3 gives the results of the means, covariances, and
variances between the intercept and slope of each variable.
The mean change in both TSK and RMDQ indicated a
small, statistically signiﬁcant decrease over time in both
variables. The within-domain covariance, relating to the
intercept and slope of the same construct,43 showed a
positive estimate between TSK intercept and slope and a
negative estimate between RMDQ intercept and slope. This
suggested that people who scored highly on the TSK at
baseline had a higher rate of decrease in scores than those
TABLE 2. Changes Over Time (Means and SDs) for Potential Mediator and Outcome Variables in the Back In Action Trial
Variable Baseline 2-mo Follow-up 6-mo Follow-up 12-mo Follow-up 24-mo Follow-up
RMDQ (23-item version) Treatment (n=119) 12.10 (5.49) 10.02 (6.27) 8.91 (6.60) 8.46 (6.90) 7.76 (6.41)
TSK (10-item version) 41.47 (8.79) 36.41 (9.51) 34.99 (9.65) 35.27 (10.32) 34.11 (9.41)
RMDQ (23-item version) Control (n=121) 11.36 (5.67) 11.44 (5.81) 10.01 (6.25) 8.99 (5.96) 9.02 (6.87)
TSK (10-item version) 41.25 (8.22) 39.96 (9.62) 39.17 (9.47) 37.55 (8.91) 38.58 (9.19)
RMDQ indicates Roland-Morris Disability Questionnaire; TSK, Tampa Scale for Kinesiophobia.
FIGURE 1. Course of 10-item TSK scores (mediator variable) for
intervention and control groups over 2 years follow-up. TSK
indicates Tampa Scale for Kinesiophobia.
FIGURE 2. Course of 23-item RMDQ scores (outcome variable)
for intervention and control groups over 2 years follow-up.
RMDQ indicates Roland-Morris Disability Questionnaire.
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who scored lower, whereas for the RMDQ, people who
scored higher at baseline had a lower rate of decrease in
scores. However, both of these estimates were very small
and did not reach statistical signiﬁcance. The between-
domain covariances gave much higher, statistically sig-
niﬁcant values. The high value between the TSK and
RMDQ slope factors suggested that as TSK scores change
the RMDQ scores also change (an important prerequisite
for mediation). The high value between the 2 intercepts
suggested that people who scored highly on the TSK are
likely to also score highly on the RMDQ. Finally, the
variances for each latent factor indicated strong individual
variation among participants, especially in the initial scores.
Treatment allocation was then added to the model as a
covariate. The model provided a very similar ﬁt to the data
as the model without the treatment group allocation vari-
able. Modiﬁcation indices indicated that allowing cova-
riation between the error terms for TSK and RMDQ scores
at 12-month follow-up, TSK score at 12-month follow-up
and RMDQ score at 2-month follow-up, and TSK and
RMDQ scores at 2-month follow-up would result in a
better ﬁtting model (w542 =172.17, P<0.05, w2/df=3.19,
CFI=0.94, RMSEA=0.10 [95% CI, 0.08-0.11],
SRMR=0.04). The covariation between TSK score at 12-
month follow-up and RMDQ score at 2-month follow-up is
less intuitive than covariances between the variables at the
same time points, but could reﬂect a relationship between
early change in disability and later change in FABs.
In the present analysis, the values of interest are the
regression coeﬃcients between treatment allocation and the
slopes for the mediator and outcome.43 Allocation to the
intervention group signiﬁcantly predicted the rate of change
for both the TSK and RMDQ measures (Table 4). The
slope values for TSK and RMDQ suggest that change in
the TSK and RMDQ measures was substantially higher in
the intervention group, particularly for the change in TSK
(0.26 and 0.65 for TSK and RMDQ scores,
respectively).
Step 3
Finally, the full mediation model was tested by adding
a path between the mediator and outcome variables. The
bold lines in Figure 3 highlight the mediating pathway.
Each of the b coeﬃcients shown in this ﬁgure represent the
direct eﬀect of each variable on the other, as indicated by
the direction of the arrow. The standardized coeﬃcients
show that the intervention is associated with a decrease in
the TSK slope (0.44) and that this decrease is associated
with a decrease in the RMDQ slope (0.79). Table 5 shows
that the mediated eﬀect (product of coeﬃcients; in this case,
FIGURE 3. Full mediation model: change in fear-avoidance beliefs (10-item TSK) as a mediator between treatment allocation and
change in disability outcome (23-item RMDQ). Total effects are taken from Table 5. b is standardized estimate; b, unstandardized
estimate. RMDQ indicates Roland-Morris Disability Questionnaire; TSK, Tampa Scale for Kinesiophobia.
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0.440.79= 0.35 [95% CI, 0.47 to 0.24]) was
statistically signiﬁcant, indicating that diﬀerences between
intervention and control in change in the observed tra-
jectory of the FABs variable mediated some of the change
in the observed trajectory of the outcome measure. How-
ever, none of the model ﬁt statistics for this ﬁnal model
suggest that it provided a good ﬁt to the data
(w632 =1095.17, P<0.05, w2/df=17.38, CFI=0.46,
RMSEA=0.26 [95% CI, 0.25-0.28], SRMR=0.36) and
modifying the model did not help to improve ﬁt.
DISCUSSION
The aim of this study was to use a more novel ana-
lytical approach to assessing mediation in an RCT dataset.
We sought to test the study’s hypothesis that change in
FABs explained the reduction in disability scores seen in the
intervention arm of the trial (ie, that change in FABs was a
mediator of the relationship between treatment allocation
and disability improvement). The results of the analyses
showed that there were associations between the inter-
vention and change in FABs, and between change in FABs
and change in disability. There was a signiﬁcant mediating
eﬀect of change in FABs on the relationship between
allocation to the active treatment and change in disability.
This suggested that targeting FABs in an intervention for
chronic LBP patients would be beneﬁcial. However, the
ﬁnal mediation model provided a poor ﬁt to the data. This
means that the model as currently hypothesized does not
fully explain how the treatment worked for this particular
patient population, as there is key information missing. The
study hypothesis, that allocation to the activation inter-
vention arm was associated with a reduction in FABs and
that this reduction was associated with a reduction in dis-
ability outcome, was therefore partially supported, but
suggests that other mediating factors must be considered.
The Back In Action trial was a complex intervention,
involving several sessions with a multidisciplinary team and
several diﬀerent components. Although several of these
sessions did focus on reducing FABs, much of the inter-
vention actually focused on goal setting and on plans to
achieve those goals. These are likely to be highly variable
depending on the individual patient, and could depend on
factors such as self-eﬃcacy or internal control, or the
patient’s relationship with their therapist. A systematic
review also found pain catastrophizing to be a potential
mediator of treatment eﬀect in interventions with a psy-
chological component in noninﬂammatory MSK pain,52
although there has been some recent debate around this
with robust mediation analysis ﬁnding contradictory
results.53 Clearly further investigation of this factor is
warranted. Both pain catastrophizing and FABs are key
components of the Fear-Avoidance Model,54 which has
been used extensively to explain the development of pain
and disability in patients with MSK pain. However,
although strong evidence exists for the predictive value of
each of these model components,55,56 studies investigating
the causal nature of these relationships have suggested that
the model does not work in the hypothesized order.57,58
This model was not tested in full as part of the present
study, but the results add to the evidence base for FABs
being potential mediators of treatment outcome, even
though the exact pathways through which this factor con-
tributes has not been fully clariﬁed as yet.
It could also be that the population included in the
intervention did not score particularly highly on the FABs
TABLE 3. Means, Covariances, Correlations, and Variances Between Mediator and Outcome Variables
Variables Estimate SE P
Means TSK intercept (baseline value) 41.14 0.56 0.00
TSK slope (change over all time points) 3.06 0.32 0.00
RMDQ intercept 11.81 0.36 0.00
RMDQ slope 1.38 0.15 0.00
Covariances TSK intercept2TSK slope b=1.06
b=0.05
2.71 0.49
TSK intercept2RMDQ intercept b=20.79
b=0.60
3.10 0.00
TSK slope2RMDQ slope b=3.64
b=0.86
0.68 0.00
RMDQ intercept2RMDQ slope b= 0.31
b= 0.04
0.79 0.69
Variances TSK intercept 52.05 6.69 0.00
TSK slope 7.93 2.30 0.00
RMDQ intercept 23.06 2.81 0.00
RMDQ slope 2.24 0.50 0.00
b is standardized estimate; b, unstandardized estimate.
RMDQ indicates Roland-Morris Disability Questionnaire; TSK, Tampa Scale for Kinesiophobia.
TABLE 4. Mean Values for Mediator and Outcome, Related to
Treatment Group Allocation
Variables Estimate SE P
Regression
coeﬃcients
TSK intercept b=0.10
b=0.01
1.12 0.93
TSK slope b= 0.26
b= 0.45
0.61 0.00
RMDQ intercept b=0.21
b=0.02
0.72 0.77
RMDQ slope b= 0.65
b= 0.22
0.29 0.02
b is standardized estimate; b, unstandardized estimate.
RMDQ indicates Roland-Morris Disability Questionnaire; TSK, Tampa
Scale for Kinesiophobia.
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measure used, which would have limited the intervention’s
ability to impact on patient scores. However, little infor-
mation is available on an acceptable cut-oﬀ for a “high”
TSK score. Previous studies using the Swedish and Dutch
versions of the 17-item TSK have recommended a cut-oﬀ of
37 for “high” fear.54,59,60 In this study, the trial authors
scored the 10-item TSK in a way that made it comparable
with the 17-item version. If these cut-oﬀs are applied to the
present study, it would appear that both the treatment and
control groups have high fear at baseline (mean score over
37), and whereas in the treatment group this score decreases
(below 37 at each follow-up point), in the control group the
scores at each follow-up point remain above this cut-oﬀ.
Comparison With Previous Literature
This analysis adds to a currently small evidence base
for treatment mediators of LBP interventions, and is the
ﬁrst study, to the authors’ knowledge, that has used latent
growth modelling for analyzing mediators in a LBP inter-
vention study. Guidelines from previous LGM studies in
other areas of health psychology were followed.39,61 A
recent study also claimed to use Cheong and colleagues’
technique to carry out their mediation analysis on a RCT
data from an intervention to prevent child behavioral
problems,62 but although this study utilized LGMs they
obtained their mediating eﬀect using the Baron and
Kenny63 approach rather than using the product of coef-
ﬁcients approach used in the present study. The latter
approach is recommended in the wider mediation liter-
ature46 suggesting that it might represent stronger evidence
of a mediated eﬀect.
Potential Limitations
The technique of latent growth modelling used to
carry out this analysis proved a useful, if complex, techni-
que for mediation analysis. It oﬀers the potential to address
a key problem within current mediation studies, temporal
sequencing, which is not currently adequately
addressed.30–32 However, it must be acknowledged that
latent growth modelling is a correlational technique and
therefore it cannot be established whether the eﬀect is in the
hypothesized direction. The use of LGMs alone, as this
study shows, cannot address temporal sequencing without
including an adequate number of time points that will
capture change when it occurs. In the present study, even
though the Back In Action study collected data across 5
time points, it did not collect any data while the inter-
vention was taking place. This limits the assessment of
treatment-mediated eﬀects as it is likely that the follow-up
scores show a more diluted eﬀect of the intervention than at
the time of participants receiving it. The analyses presented
here showed that change in both FABs and disability
happens early on, but it is still not possible to see when
these variables changed and crucially, which changed ﬁrst.
One way of potentially addressing this issue would have
been to look at the intercept of the mediating variable and
the slope of the outcome, rather than the slopes of both
variables (to see whether baseline levels of FABs predict
change in disability),64 but that would have been illogical in
this analysis as the hypothesis was around change in the
mediator and the outcome. Looking at change in the
mediator at an earlier stage than change in the outcome is
another option, but again not possible in this analysis as the
ﬁrst follow-up point was 2 months posttreatment, at which
any change that was expected to happen in both the
mediator and outcome variables would have already
occurred. However, such analysis is possible using LGMs
provided that there are enough time points to allow
examination of early and later change. This again stresses
the need for assessment points during treatment. This
would of course need to be balanced with the consideration
of response burden for participants and the potential for
increased dropout this additional burden may cause.
The ﬁnal mediation model was also found to be a poor
ﬁt to the data, suggesting other factors might be responsible
for the treatment eﬀect. We acknowledge that only testing a
single potential mediator is limiting, and that other factors
measured in the original study such as depression and
anxiety could also be important potential mediators.
However, these factors (and others, such as those men-
tioned earlier) were not considered as mediating factors in
the original study, so they were not tested. It could be that
the addition of other factors would have improved the ﬁt of
the model.
Implications for Clinical Practice and Research
Clinically, the ﬁndings from this study suggest that
FABs play a role in the explanation of treatment outcome
when a treatment speciﬁcally targets this factor. Future
treatments should perhaps include only patients who are
found to be highly fear avoidant, or tailor treatment to
focus FAB reduction on patients who are most severe.
However, this analysis represents only 1 study and more
research is needed to support these ﬁndings, preferably
research that accounts for the limitations discussed above.
Few additional variables that could have played a key role
in the success of this intervention (such as self-eﬃcacy) were
measured, and the role of other factors in this intervention
are therefore unclear. Another concern is that the measure
of FABs available in this dataset has not been validated
previously, and its internal consistency in this dataset was
questionable. A stronger measure of FABs, to ensure more
TABLE 5. Mediating Effect of Change in Fear-Avoidance Beliefs (10-Item TSK) on the Relationship Between Treatment Allocation and
Change in Disability (23-Item RMDQ)
Model
Eﬀect Standardized Estimates (95% CI) Unstandardized Estimates (95% CI)
RMDQ (23-item)* Total (c´) 0.22 (0.40 to 0.02) 0.66 (1.20 to 0.08)
Direct (c) 0.11 (0.11 to 0.33) 0.31 (0.31 to 1.01)
Indirect (ab) 0.35 (0.48 to 0.23) 1.03 (1.49 to 0.67)
*Residualized change.
CI indicates conﬁdence interval; RMDQ, Roland-Morris Disability Questionnaire; TSK, Tampa Scale for Kinesiophobia.
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conﬁdence that this construct is indeed a mediator of
outcome, is required in future studies.
To improve the delivery of future interventions, it
would also be helpful to see which aspect of the inter-
vention led to a change in FABs. For example, if this was
after the ﬁrst session, when fear of pain was explicitly dis-
cussed, it could be that this session was the one that was
important in changing FABs. Measurements taken during
the treatment period would give much more information on
key variables that the intervention aimed to change, so that
future interventions can be tailored to only include sessions
found to impact on factors of importance.
CONCLUSIONS
The reduction of FABs through a multidisciplinary
intervention was found to be a signiﬁcant mediating factor
for the reduction of disability in chronic LBP patients in the
Back In Action Trial. This study therefore supports the role
of training clinicians in being able to target FABs as part of
their overall skillset. One key issue still not resolved by this
study is that of temporality. Future studies of treatment
mediation need to address temporal relationships by
including measures of key mediators and outcomes during
the treatment period, to more conﬁdently ascertain when
reductions in fear tend to occur and thereby inform clini-
cians about when FABs should be targeted within a course
of treatment.
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